By David Elder (JPAG Chair), Dr Conor Jamieson (Sandwell and West Birmingham NHS Trust), Dr Gary Scrivens (Pfizer), Dr Jonathan Bright (AstraZeneca), Dr Maria Krisch (FreeThink Technologies), Dr Paul Fullerton (AMRI), John Cleverley (Clarivate Analytics), Rachel Orr (GlaxoSmithKline), Susan Smith (AstraZeneca)
Published in: European Pharmaceutical Review
Published on: September 4, 2019
The Joint Pharmaceutical Analysis Group (JPAG) held a stability meeting at the Royal Society of Chemistry’s headquarters in London earlier in 2019. Attended by 65 delegates, its focus was on developments in stability testing and evaluation. This article is a summary of the presentations made at the meeting.
